NCT02873351: A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration |
|
|
| Withdrawn | 2 | 0 | US | carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg | Snyder, Robert W., M.D., Ph.D., P.C. | Age-related Macular Degeneration | 12/20 | 12/20 | | |
